Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

The role of the thalamus and hippocampus in episodic memory performance in patients with multiple sclerosis.

Koenig KA, Rao SM, Lowe MJ, Lin J, Sakaie KE, Stone L, Bermel RA, Trapp BD, Phillips MD.

Mult Scler. 2018 Mar 1:1352458518760716. doi: 10.1177/1352458518760716. [Epub ahead of print]

PMID:
29512427
2.

Unravelling neurodegeneration in multiple sclerosis.

Bermel RA.

Lancet Neurol. 2017 Oct;16(10):764-766. doi: 10.1016/S1474-4422(17)30302-2. Epub 2017 Sep 12. No abstract available.

PMID:
28920874
3.

Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up.

Hersh CM, Love TE, Bandyopadhyay A, Cohn S, Hara-Cleaver C, Bermel RA, Fox RJ, Cohen JA, Ontaneda D.

Mult Scler J Exp Transl Clin. 2017 Aug 24;3(3):2055217317715485. doi: 10.1177/2055217317715485. eCollection 2017 Jul-Sep.

4.

Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis.

Cohen JA, Imrey PB, Planchon SM, Bermel RA, Fisher E, Fox RJ, Bar-Or A, Sharp SL, Skaramagas TT, Jagodnik P, Karafa M, Morrison S, Reese Koc J, Gerson SL, Lazarus HM.

Mult Scler. 2018 Apr;24(4):501-511. doi: 10.1177/1352458517703802. Epub 2017 Apr 6.

PMID:
28381130
5.

Processing speed test: Validation of a self-administered, iPad®-based tool for screening cognitive dysfunction in a clinic setting.

Rao SM, Losinski G, Mourany L, Schindler D, Mamone B, Reece C, Kemeny D, Narayanan S, Miller DM, Bethoux F, Bermel RA, Rudick R, Alberts J.

Mult Scler. 2017 Dec;23(14):1929-1937. doi: 10.1177/1352458516688955. Epub 2017 Jan 12.

PMID:
28080262
6.

Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up.

Hersh CM, Love TE, Cohn S, Hara-Cleaver C, Bermel RA, Fox RJ, Cohen JA, Ontaneda D.

Mult Scler Relat Disord. 2016 Nov;10:44-52. doi: 10.1016/j.msard.2016.08.002. Epub 2016 Aug 8.

PMID:
27919497
7.

Heterogeneous depression trajectories in multiple sclerosis patients.

Gunzler DD, Morris N, Perzynski A, Ontaneda D, Briggs F, Miller D, Bermel RA.

Mult Scler Relat Disord. 2016 Sep;9:163-9. doi: 10.1016/j.msard.2016.08.004. Epub 2016 Aug 5.

8.

Incidence, characterization, and clinical impact analysis of peginterferon beta1a immunogenicity in patients with multiple sclerosis in the ADVANCE trial.

White JT, Newsome SD, Kieseier BC, Bermel RA, Cui Y, Seddighzadeh A, Hung S, Crossman M, Subramanyam M.

Ther Adv Neurol Disord. 2016 Jul;9(4):239-49. doi: 10.1177/1756285616633967. Epub 2016 Mar 10.

9.

Relapses in multiple sclerosis: Relationship to disability.

Goodin DS, Reder AT, Bermel RA, Cutter GR, Fox RJ, John GR, Lublin FD, Lucchinetti CF, Miller AE, Pelletier D, Racke MK, Trapp BD, Vartanian T, Waubant E.

Mult Scler Relat Disord. 2016 Mar;6:10-20. doi: 10.1016/j.msard.2015.09.002. Epub 2015 Sep 8. Review.

PMID:
27063617
10.

Optical Coherence Tomography for the Detection of Remote Optic Neuritis in Multiple Sclerosis.

Xu LT, Bermel RA, Nowacki AS, Kaiser PK.

J Neuroimaging. 2016 May;26(3):283-8. doi: 10.1111/jon.12326. Epub 2016 Jan 15.

PMID:
26773711
11.

The relationship between cognitive function and high-resolution diffusion tensor MRI of the cingulum bundle in multiple sclerosis.

Koenig KA, Sakaie KE, Lowe MJ, Lin J, Stone L, Bermel RA, Beall EB, Rao SM, Trapp BD, Phillips MD.

Mult Scler. 2015 Dec;21(14):1794-801. doi: 10.1177/1352458515576983. Epub 2015 Jun 23.

12.

Fingolimod first-dose effects in patients with relapsing multiple sclerosis concomitantly receiving selective serotonin-reuptake inhibitors.

Bermel RA, Hashmonay R, Meng X, Randhawa S, von Rosenstiel P, Sfikas N, Kantor D.

Mult Scler Relat Disord. 2015 May;4(3):273-80. doi: 10.1016/j.msard.2015.04.002. Epub 2015 Apr 13.

13.

Using MRI to make informed clinical decisions in multiple sclerosis care.

Bermel RA, Naismith RT.

Curr Opin Neurol. 2015 Jun;28(3):244-9. doi: 10.1097/WCO.0000000000000204. Review.

PMID:
25887772
14.

Experience with fingolimod in clinical practice.

Hersh CM, Hara-Cleaver C, Rudick RA, Cohen JA, Bermel RA, Ontaneda D.

Int J Neurosci. 2015;125(9):678-85. doi: 10.3109/00207454.2014.969839. Epub 2014 Oct 29.

15.

Retrograde trans-synaptic degeneration in MS: a missing link?

Bermel RA, Villoslada P.

Neurology. 2014 Jun 17;82(24):2152-3. doi: 10.1212/WNL.0000000000000532. Epub 2014 May 16. No abstract available.

PMID:
24838792
16.

Simple MRI metrics contribute to optimal care of the patient with multiple sclerosis.

Simon JH, Bermel RA, Rudick RA.

AJNR Am J Neuroradiol. 2014 May;35(5):831-2. doi: 10.3174/ajnr.A3937. Epub 2014 Apr 3. No abstract available.

17.

Hippocampal volume is related to cognitive decline and fornicial diffusion measures in multiple sclerosis.

Koenig KA, Sakaie KE, Lowe MJ, Lin J, Stone L, Bermel RA, Beall EB, Rao SM, Trapp BD, Phillips MD.

Magn Reson Imaging. 2014 May;32(4):354-8. doi: 10.1016/j.mri.2013.12.012. Epub 2013 Dec 30.

18.

Optic neuritis and the evaluation of visual impairment in multiple sclerosis.

Bermel RA, Balcer LJ.

Continuum (Minneap Minn). 2013 Aug;19(4 Multiple Sclerosis):1074-86. doi: 10.1212/01.CON.0000433282.00221.7e. Review.

PMID:
23917102
19.

Sex differences in resting-state functional connectivity in multiple sclerosis.

Koenig KA, Lowe MJ, Lin J, Sakaie KE, Stone L, Bermel RA, Beall EB, Rao SM, Trapp BD, Phillips MD.

AJNR Am J Neuroradiol. 2013 Dec;34(12):2304-11. doi: 10.3174/ajnr.A3630. Epub 2013 Jun 27.

20.
21.

Sensorimotor cortex gamma-aminobutyric acid concentration correlates with impaired performance in patients with MS.

Bhattacharyya PK, Phillips MD, Stone LA, Bermel RA, Lowe MJ.

AJNR Am J Neuroradiol. 2013 Sep;34(9):1733-9. doi: 10.3174/ajnr.A3483. Epub 2013 Mar 14.

22.

Predictors of long-term outcome in multiple sclerosis patients treated with interferon β.

Bermel RA, You X, Foulds P, Hyde R, Simon JH, Fisher E, Rudick RA.

Ann Neurol. 2013 Jan;73(1):95-103. doi: 10.1002/ana.23758.

PMID:
23378325
23.

High spatial and angular resolution diffusion-weighted imaging reveals forniceal damage related to memory impairment.

Koenig KA, Sakaie KE, Lowe MJ, Lin J, Stone L, Bermel RA, Beall EB, Rao SM, Trapp BD, Phillips MD.

Magn Reson Imaging. 2013 Jun;31(5):695-9. doi: 10.1016/j.mri.2012.10.030. Epub 2013 Jan 5.

24.

Neurodegeneration and inflammation in MS: the eye teaches us about the storm.

Bermel RA, Inglese M.

Neurology. 2013 Jan 1;80(1):19-20. doi: 10.1212/WNL.0b013e31827b1b6c. No abstract available.

PMID:
23267029
25.

Early tolerability and safety of fingolimod in clinical practice.

Ontaneda D, Hara-Cleaver C, Rudick RA, Cohen JA, Bermel RA.

J Neurol Sci. 2012 Dec 15;323(1-2):167-72. doi: 10.1016/j.jns.2012.09.009. Epub 2012 Oct 3.

26.

Fulminant cerebral demyelination in neuromyelitis optica.

Newey CR, Bermel RA.

Neurology. 2011 Jul 12;77(2):193. doi: 10.1212/WNL.0b013e3182242d6e. No abstract available.

PMID:
21747076
27.

Multiple sclerosis: advances in understanding pathogenesis and emergence of oral treatment options.

Bermel RA, Cohen JA.

Lancet Neurol. 2011 Jan;10(1):4-5. doi: 10.1016/S1474-4422(10)70282-9. No abstract available.

PMID:
21163434
28.

MRI in multiple sclerosis.

Bermel RA, Fox RJ.

Continuum (Minneap Minn). 2010 Oct;16(5 Multiple Sclerosis):37-57. doi: 10.1212/01.CON.0000389933.77036.14.

PMID:
22810597
29.

Diagnosing multiple sclerosis at a later age: more than just progressive myelopathy.

Bermel RA, Rae-Grant AD, Fox RJ.

Mult Scler. 2010 Nov;16(11):1335-40. doi: 10.1177/1352458510377334. Epub 2010 Jul 29.

PMID:
20670982
30.

Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study.

Bermel RA, Weinstock-Guttman B, Bourdette D, Foulds P, You X, Rudick RA.

Mult Scler. 2010 May;16(5):588-96. doi: 10.1177/1352458509360549. Epub 2010 Feb 18.

PMID:
20167591
31.

Picturing injury and recovery with diffusion tensor imaging: the eyes have it.

Bermel RA, Fox RJ.

Neurology. 2009 Feb 17;72(7):584-5. doi: 10.1212/01.wnl.0000336559.52816.16. Epub 2008 Dec 10. No abstract available.

PMID:
19073946
32.

The use of MR imaging as an outcome measure in multiple sclerosis clinical trials.

Bermel RA, Fisher E, Cohen JA.

Neuroimaging Clin N Am. 2008 Nov;18(4):687-701, xi. doi: 10.1016/j.nic.2008.06.008. Review.

PMID:
19068409
33.

Interferon-beta treatment for multiple sclerosis.

Bermel RA, Rudick RA.

Neurotherapeutics. 2007 Oct;4(4):633-46. Review.

PMID:
17920544
34.

The measurement and clinical relevance of brain atrophy in multiple sclerosis.

Bermel RA, Bakshi R.

Lancet Neurol. 2006 Feb;5(2):158-70. Review.

PMID:
16426992
35.

Measurement of brain and spinal cord atrophy by magnetic resonance imaging as a tool to monitor multiple sclerosis.

Bakshi R, Dandamudi VS, Neema M, De C, Bermel RA.

J Neuroimaging. 2005;15(4 Suppl):30S-45S. Review.

PMID:
16385017
36.

Prediction of longitudinal brain atrophy in multiple sclerosis by gray matter magnetic resonance imaging T2 hypointensity.

Bermel RA, Puli SR, Rudick RA, Weinstock-Guttman B, Fisher E, Munschauer FE 3rd, Bakshi R.

Arch Neurol. 2005 Sep;62(9):1371-6.

37.

A semiautomated measure of whole-brain atrophy in multiple sclerosis.

Bermel RA, Sharma J, Tjoa CW, Puli SR, Bakshi R.

J Neurol Sci. 2003 Apr 15;208(1-2):57-65.

PMID:
12639726
38.

Selective caudate atrophy in multiple sclerosis: a 3D MRI parcellation study.

Bermel RA, Innus MD, Tjoa CW, Bakshi R.

Neuroreport. 2003 Mar 3;14(3):335-9.

PMID:
12634479
39.

Bicaudate ratio as a magnetic resonance imaging marker of brain atrophy in multiple sclerosis.

Bermel RA, Bakshi R, Tjoa C, Puli SR, Jacobs L.

Arch Neurol. 2002 Feb;59(2):275-80.

PMID:
11843699
40.

T2 hypointensity in the deep gray matter of patients with multiple sclerosis: a quantitative magnetic resonance imaging study.

Bakshi R, Benedict RH, Bermel RA, Caruthers SD, Puli SR, Tjoa CW, Fabiano AJ, Jacobs L.

Arch Neurol. 2002 Jan;59(1):62-8.

PMID:
11790232
42.

Stereoselective inhibition of dopaminergic activity by gamma vinyl-GABA following a nicotine or cocaine challenge: a PET/microdialysis study.

Schiffer WK, Gerasimov MR, Bermel RA, Brodie JD, Dewey SL.

Life Sci. 2000 Feb 18;66(13):PL169-73.

PMID:
10737423

Supplemental Content

Loading ...
Support Center